The demonstration of a predictive role of ABCC3 expression in NK cells, if confirmed on a larger number of patients, may have a relevant impact on selecting patients affected by GBM, and possibly other cancers, likely to obtain clinical benefit from chemoimmunotherapy. Here, ABCC3 is linked to glioblastoma.